TY - JOUR
T1 - Development and validation of an in vitro resazurin-based susceptibility assay against madurella mycetomatis
AU - Algaffar, S. O.Abd
AU - Verbon, A.
AU - van de Sande, W. W.J.
AU - Khalid, S. A.
N1 - Publisher Copyright:
© 2021 Abd Algaffar et al.
PY - 2021/3
Y1 - 2021/3
N2 - We present an in vitro susceptibility assay for Madurella mycetomatis hyphae using resazurin for endpoint reading. Using this assay, reproducible MICs were obtained for amphotericin B, itraconazole, voriconazole, posaconazole, terbinafine, and micafungin. Results were comparable with those of a 2,3-bis-(2-methoxy-4- nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT)-based susceptibility assay. The lowest MICs were obtained for itraconazole and posaconazole (MIC50, 0.016mg/ml) followed by voriconazole (MIC50, 0.063mg/ml). Amphotericin B, micafungin, and terbinafine appeared much less effective.
AB - We present an in vitro susceptibility assay for Madurella mycetomatis hyphae using resazurin for endpoint reading. Using this assay, reproducible MICs were obtained for amphotericin B, itraconazole, voriconazole, posaconazole, terbinafine, and micafungin. Results were comparable with those of a 2,3-bis-(2-methoxy-4- nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT)-based susceptibility assay. The lowest MICs were obtained for itraconazole and posaconazole (MIC50, 0.016mg/ml) followed by voriconazole (MIC50, 0.063mg/ml). Amphotericin B, micafungin, and terbinafine appeared much less effective.
UR - http://www.scopus.com/inward/record.url?scp=85101774114&partnerID=8YFLogxK
U2 - 10.1128/AAC.01338-20
DO - 10.1128/AAC.01338-20
M3 - Article
C2 - 33318015
AN - SCOPUS:85101774114
SN - 0066-4804
VL - 65
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 3
M1 - e01338-20
ER -
